2020
Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database.
Uhlig J, Nie J, Stein S, Cecchini M, Lacy J, Kim H. Neuroendocrine and carcinoid tumors of the gastrointestinal tract: Epidemiology and outcomes from the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 609-609. DOI: 10.1200/jco.2020.38.4_suppl.609.Peer-Reviewed Original ResearchNational Cancer DatabaseNeuroendocrine tumorsOverall survivalSmall intestineSurgical resectionYounger patientsCancer DatabaseGastrointestinal tractImproved overall survivalPrimary disease siteLonger overall survivalPrimary cancer siteProportional hazards modelAfrican AmericansLower stageConcurrent chemotherapyMultivariable adjustmentAdult patientsMost metastasesPatient agePatient demographicsIndependent prognosticatorCarcinoid tumorsHepatic metastasesTumor size
2015
Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC).
James E, Cong X, Yao X, Hahn C, Kaley K, Li J, Kortmansky J, Fischbach N, Cha C, Salem R, Stein S, Hochster H, Lacy J. Final analysis of a phase II study of Yale-modified FOLFIRINOX (mFOLFIRINOX) in metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2015, 33: 395-395. DOI: 10.1200/jco.2015.33.3_suppl.395.Peer-Reviewed Original ResearchMetastatic pancreatic cancerResponse rateProphylactic pegfilgrastimEntire cohortPhase II open-label studyFinal analysisECOG PS 0ECOG PS 0/1Grade 3/4 toxicitiesOpen-label studyPhase II studyBolus 5FUPS 0/1Febrile neutropeniaLAPC patientsPeritoneal diseaseII studyPS 0Surgical resectionUnacceptable toxicityImproved tolerabilityPeripheral neuropathyMetastatic sitesPancreatic cancerFOLFIRINOX
2014
Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC).
James E, Yao X, Cong X, Stein S, Kaley K, Hahn C, Cha C, Salem R, Hochster H, Lacy J. Interim analysis of a phase II study of dose-modified FOLFIRINOX (mFOLFIRINOX) in locally advanced (LAPC) and metastatic pancreatic cancer (MPC). Journal Of Clinical Oncology 2014, 32: 256-256. DOI: 10.1200/jco.2014.32.3_suppl.256.Peer-Reviewed Original ResearchMetastatic pancreatic cancerAdvanced pancreatic cancerPancreatic cancerFebrile neutropeniaResponse rateEvaluable ptsProphylactic pegfilgrastimInterim analysisPhase II open-label studyGrade 3/4 toxicitiesOpen-label studyPhase II studyFDG-PET scansSimilar response ratesECOG PSNeoadjuvant FOLFIRINOXUnderwent resectionII studySurgical resectionUnacceptable toxicityPET responseFOLFIRINOXRetrospective analysisDose reductionLabel study
2012
Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).
Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Lacy J. Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: e14534-e14534. DOI: 10.1200/jco.2012.30.15_suppl.e14534.Peer-Reviewed Original ResearchAdvanced pancreatic cancerMetastatic pancreatic cancerPancreatic cancerOverall survivalMetastatic PCProphylactic pegfilgrastimAdvanced unresectable pancreatic cancerECOG PS 0/1Efficacy of FOLFIRINOXGrade 3/4 fatigueUnresectable pancreatic cancerYale Cancer CenterSingle institution experienceKaplan-Meier methodWarrants further evaluationDose attenuationChemotherapy 5PS 0/1Free survivalSurgical resectionUnacceptable toxicityImproved tolerabilityPhysician's discretionRetrospective reviewInstitution experienceSingle-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC).
Gunturu K, Thumar J, Hochster H, Stein S, Yao X, Cong X, Hahn C, Kaley K, Lacy J. Single-institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). Journal Of Clinical Oncology 2012, 30: 330-330. DOI: 10.1200/jco.2012.30.4_suppl.330.Peer-Reviewed Original ResearchAdvanced pancreatic cancerPancreatic cancerProphylactic pegfilgrastimMetastatic PCFull dosesAdvanced unresectable pancreatic cancerECOG PS 0Efficacy of FOLFIRINOXRelative dose intensityUnresectable pancreatic cancerYale Cancer CenterMetastatic pancreatic cancerSingle institution experienceWarrants further evaluationCycle 1Age 60 yrEquivalent response ratesDose attenuationChemotherapy 5Evaluable ptsFebrile neutropeniaUnderwent resectionDose intensitySurgical resectionUnacceptable toxicity